Institute for Research in Immunology and Cancer-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Institute for Research in Immunology and Cancer - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014283
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Institute for Research in Immunology and Cancer (IRICoR), a subsidiary of University of Montreal is a non-profit research institute that offers drug discovery and commercialization services. The institute offers discovery, development and commercialization of novel drugs in oncology. It has invested in innovative projects through its process of selection, monitoring, prioritization and supporting projects by identifying the best development partners. IRICoR provides optimizing and accelerating the process of commercializing through its partnerships with academia and industry. The institute also operates through bioscience companies, universities, therapeutic centers and others. IRICoR is headquartered in Montreal, Quebec, Canada.

Institute for Research in Immunology and Cancer – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Institute for Research in Immunology and Cancer, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Institute for Research in Immunology and Cancer, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Institute for Research in Immunology and Cancer, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Institute for Research in Immunology and Cancer, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Institute for Research in Immunology and Cancer, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Institute for Research in Immunology and Cancer, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Cyclenium Pharma Enters into Research Agreement with IRICoR 10
Encycle Therapeutics Enters into Co-Development Agreement with IRICoR, UdeM and MaRS Innovation 11
NeoMed Enters Into Drug Discovery And Development Agreement With IRICoR 12
Licensing Agreements 13
Domain Therapeutics Extends its Licensing Agreement with Universite de Montreal and McGill University 13
IRICoR And University Of Montreal Enter Into Licensing Agreement With Pfizer 15
University Of Montreal Enters Into Licensing Agreement With Bristol-Myers Squibb 17
Institute for Research in Immunology and Cancer – Key Competitors 18
Institute for Research in Immunology and Cancer – Key Employees 19
Institute for Research in Immunology and Cancer – Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Institute for Research in Immunology and Cancer, Pharmaceuticals & Healthcare, Key Facts 2
Institute for Research in Immunology and Cancer, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Institute for Research in Immunology and Cancer, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Institute for Research in Immunology and Cancer, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Institute for Research in Immunology and Cancer, Deals By Therapy Area, 2011 to YTD 2017 8
Institute for Research in Immunology and Cancer, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Cyclenium Pharma Enters into Research Agreement with IRICoR 10
Encycle Therapeutics Enters into Co-Development Agreement with IRICoR, UdeM and MaRS Innovation 11
NeoMed Enters Into Drug Discovery And Development Agreement With IRICoR 12
Domain Therapeutics Extends its Licensing Agreement with Universite de Montreal and McGill University 13
IRICoR And University Of Montreal Enter Into Licensing Agreement With Pfizer 15
University Of Montreal Enters Into Licensing Agreement With Bristol-Myers Squibb 17
Institute for Research in Immunology and Cancer, Key Competitors 18
Institute for Research in Immunology and Cancer, Key Employees 19

★海外企業調査レポート[Institute for Research in Immunology and Cancer-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pharmagest Interactive SA (PHA):企業の財務・戦略的SWOT分析
    Summary Pharmagest Interactive SA (Pharmagest Interactive) is a technology company that develops and markets professional IT solutions for pharmacies and pharmaceutical industries. The company operates through four divisions such as pharmaceutical, fintech, e-health, and health and medico-social div …
  • IDT Corporation:企業の戦略・SWOT・財務情報
    IDT Corporation - Strategy, SWOT and Corporate Finance Report Summary IDT Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Targa Resources Partners LP (NGLS PR A):企業の財務・戦略的SWOT分析
    Targa Resources Partners LP (NGLS PR A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Red Rock Resorts, Inc. (RRR):企業の財務・戦略的SWOT分析
    Red Rock Resorts, Inc. (RRR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • El Pollo Loco Holdings, Inc.:企業の戦略・SWOT・財務情報
    El Pollo Loco Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary El Pollo Loco Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Axcella Health Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Axcella Health Inc (Axcella), formerly Pronutria Biosciences Inc is a developer of disease-specific amino acid profiles. The company’s lead clinical-stage candidates AXA are based on cell-specific sets of amino acids that regulate multiple biological pathways. Its amino acid therapies helps …
  • NeoGenomics Inc (NEO):企業の財務・戦略的SWOT分析
    Summary NeoGenomics Inc (NeoGenomics) is a cancer diagnostics and pharma services company that offers diagnostic, prognostic and predictive testing services. The company offers testing services with various technologies such as cytogenetics, fluorescence in-situ hybridization, flow cytometry, immuno …
  • Cypark Resources Berhad (CYPARK):企業の財務・戦略的SWOT分析
    Summary Cypark Resources Berhad (CRB) is a clean technology company that offers environmental engineering services. The company offers engineering and technology services on transforming dump sites to an economic and environmental boon. Its services include environmental remediation, integrated wast …
  • Gentera SAB de CV (GENTERA):企業の財務・戦略的SWOT分析
    Gentera SAB de CV (GENTERA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Bicycle Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Bicycle Therapeutics Ltd (Bicycle Therapeutics) is a biotechnology company that develops bicyclic peptides Medicines for the treatment of cancers and other debilitating diseases. The company's proprietary bicyclic peptide technology enables systematic cyclisation of peptides and helps to ide …
  • HDFC Bank Ltd:企業のM&A・事業提携・投資動向
    HDFC Bank Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HDFC Bank Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Reply S.p.A. (REY):企業の財務・戦略的SWOT分析
    Reply S.p.A. (REY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • MYOS RENS Technology Inc (MYOS):企業の財務・戦略的SWOT分析
    Summary MYOS RENS Technology Inc (MYOS RENS), formerly MYOS Corp is a bionutrition and biotherapeutics company that discovers, develops and commercializes products that improve muscle health and function. The company offers fortetropin, a unique bioactive composition derived from fertilized chicken …
  • Lixil Group Corporation (5938):企業の財務・戦略的SWOT分析
    Lixil Group Corporation (5938) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • IndiPharm Inc-製薬・医療分野:企業M&A・提携分析
    Summary IndiPharm Inc (IndiPharm) is a clinical research organization that provides drug safety services to support clinical research and marketed products. The organization offers CRO services such as preparing and filing regulatory submissions, obtaining required import and export licenses, protoc …
  • MallInckrodt Plc (MNK):企業の財務・戦略的SWOT分析
    MallInckrodt Plc (MNK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Rexel S.A.:戦略・SWOT・企業財務分析
    Rexel S.A. - Strategy, SWOT and Corporate Finance Report Summary Rexel S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Journey Energy Inc (JOY):石油・ガス:M&Aディール及び事業提携情報
    Summary Journey Energy Inc (Journey Energy), a subsidiary of Maples Investments LP, is an oil and gas company that offers exploration, development and production oil and natural gas assets. The company provides horizontal and multi-frac drilling, and secondary recovery methods that helps in acquirin …
  • bet-at-home.com AG (ACX):企業の財務・戦略的SWOT分析
    bet-at-home.com AG (ACX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Macmahon Holdings Ltd:企業の戦略・SWOT・財務情報
    Macmahon Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Macmahon Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆